Moderna shares rose after the announcement of 94.5 per cent efficiency in its vaccine COVID-19, according to preliminary data of final phase III trials. Unlike the Pfizer vaccine, vaccine Moderna does not require storage at ultra low temperature.
Stock Moderna (MRNA), an increase of 357% since the beginning of the year, rose more than 15% in the course of trading Monday amid news about 94,5% of the efficacy of the vaccine campaign against COVID-19.
Moderna said it plans to apply for permission to use in case of emergency, the Management on sanitary inspection behind quality of foodstuff and medicines (FDA) “in the coming weeks.”
Major stock indexes also rose after the news.
The company Moderna is in the final phase of the study its vaccine against the coronavirus, which as vaccine Pfizer (PFE) and BioNTech (BNTX), based on the technology of RNA (mRNA).
Data were obtained from studies Moderna with about 30 000 participants, among whom were many representatives of different races, while 42% of participants had disease or age that put them at high risk for severe disease.
A week ago, Pfizer and BioNTech became the first companies that reported high efficiency (over 90%) of its vaccine COVID-19.
However, the advantage of the vaccine from the Moderna are that it does not require storage at ultra low temperature. While the vaccine “BNT162b1” Pfizer requires conditions in -34.4 °C, which complicates storage and transportation for vaccines Moderna valid range is from -7,7 °C to -2.2 °C, which simplifies its distribution.
Manual Moderna said that confidently, not only in efficiency, but in the safety of vaccines, as these studies show that the vaccine is generally well tolerated, and most side effects among the participants assessed as light or moderate. Side effects included pain at the injection site, and after the second dose of fatigue, muscle pain and headaches.
Moderna announced that it plans “very soon” to test the vaccine on teenagers, and then children up to 12 years. The company will also continue to collect additional data regarding safety and efficacy, even after filing with the FDA.
According to the promise Moderna, by the end of the year it intends to deliver about 20 million doses in the United States. The current plan of the company in respect of the supply worldwide by 2021 ranges from 500 million to 1 billion doses.
In August, Moderna received an order for 100 million doses of its vaccine from the US government the sum of $1.53 billion with the option to purchase up to 400 million additional doses.
If vaccines Pfizer and BioNTech and vaccine Moderna will be approved by the FDA, Americans can get about 70 million doses of vaccine until the end of 2020.